Neuromyelitis Optica Consortium Act

United States116th CongressHR-321House of Representatives
Updated: Jan 25, 2019

Summary

Neuromyelitis Optica Consortium Act This bill requires the National Institutes of Health to establish, administer, and coordinate a national consortium on neuromyelitis optica (NMO), which is a neurological disease that can cause blindness and paralysis. The consortium must award grants for research on the causes of, and the risk factors and biomarkers associated with, NMO; assemble a panel of experts to provide guidance and recommendations on research design and protocols; and designate a central laboratory to collect and analyze data from this research and to make the data and analysis available to researchers.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

  1. Introduced in House

  2. Referred to the House Committee on Energy and Commerce.

    House of Representatives

  3. Referred to the Subcommittee on Health.

    House of Representatives

All available records shown.